

# Mass fragmentographic determination of cholecalciferol and 25-hydroxycholecalciferol in human serum

B. Zagalak, H.-Ch. Curtius, Rosmarie Foschi, Gabrielle Wipf, U. Redweik and Maria-Jolanta Zagalak

University of Zurich, Department of Pediatrics, Division of Medical Chemistry, Kinderspital, CH-8032 Zurich (Switzerland), 22 May 1978

**Summary.** The serum extracts were purified by column-, thin layer- and high pressure liquid chromatography. Deuterated cholecalciferol and deuterated 25-hydroxycholecalciferol were used as internal standards. The quantitative analysis was performed using GC-mass fragmentography technique of TMS-ethers.

Many methods have been developed for the determination of vitamin D and its metabolites<sup>1</sup>. Some of them are based on the protein-binding technique<sup>2-4</sup>; others use gas chromatography or a gas chromatography - mass spectrometry technique<sup>1,5-9</sup>. The sensitivity and specificity of proposed assays varies and also depends on other parameters, such as extraction, choice of internal standards and occurrence of biological background in a sample<sup>1,10,11</sup>. The well-developed gas chromatography and simple electron impact fragmentation patterns of trimethylsilyl ethers of cholecalciferol and its metabolites are very well suited to the mass fragmentographic technique. The GC-SIM method presented here could also be applied for specific investigations of vitamin D metabolism in complex biological systems.

Using known procedures<sup>1,12-15</sup>, we synthesized the internal standards **1**, **2**, and **3** (cholecalciferol-3,4-d<sub>2</sub>, cholecalciferol-2,2,3,4,4,6-d<sub>6</sub> and 25-hydroxycholecalciferol-26(27)-d<sub>3</sub> from cholesterol-3,4 $\beta$ -d<sub>2</sub><sup>16</sup>, cholesterol-2,2,3,4,4,6-d<sub>6</sub>, and 25-hydroxycholesterol-26(27)-d<sub>3</sub><sup>8,17</sup>, respectively. Cholesterol-d<sub>6</sub> was prepared from cholest-4-en-3-one which was labelled in D<sub>2</sub>O: D<sub>2</sub>SO<sub>4</sub>: dioxane. The resulting cholest-4-en-3-one-2,2,4,6,6-d<sub>5</sub> was acetylated and reduced with sodium borodeuteride in MeOD<sup>18</sup>.

**Assay.** 5 ml serum sample was mixed with 200 ng of **1** (or **2**) and 200 ng of **3**, 10 ml of water, 31 ml of methanol and 62 ml of dichloromethane. The sample was extracted for 30 min by shaking, the lower phase collected and the extraction repeated with 5 ml of methanol and 50 ml of dichloromethane. The combined extracts were evaporated to dryness and applied to a small alumina column, washed with n-hexane and finally eluted with ethanol. The ethanol-

ic eluate was further purified on an alumina TLC plate using 3% methanol in dichloromethane as a solvent system. Zones of cholecalciferol and 25-hydroxycholecalciferol were removed from the plate and eluted with ethanol. The eluates were further purified by high-pressure liquid chromatography in order to remove traces of cholesterol and other impurities. The HPLC of cholecalciferol was performed on a 4% silver nitrate-LiChrosorb SI 60 column (0.3  $\times$  25 cm, 10  $\mu$ m) with 4% tetrahydrofuran in n-hexane as a solvent system (flow 3.1 ml/min, 68 bar, retention times (R<sub>t</sub>): cholecalciferol, 16 min 10 sec; cholesterol, 19 min 15 sec). The 25-hydroxycholecalciferol eluate was chromatographed on a LiChrosorb SI 60 column (0.3  $\times$  25 cm, 10  $\mu$ m (Merck)) with 2% MeOH in dichloromethane as a solvent system (flow 0.3 ml/min, 35 bar). The retention times (R<sub>t</sub>) were: cholecalciferol, 5 min 47 sec; cholesterol, 6 min 39 sec; 25-hydroxycholecalciferol, 9 min 15 sec.

The samples were collected, evaporated, dried and finally silylated at room temperature with 50  $\mu$ l of the mixture of N,O-bis (trimethylsilyl)-trifluoroacetamide (BSTFA) and trimethylchlorosilane (TMCS) in the ratio 4:1. The samples were analyzed in a GC-MS apparatus equipped with SE-30 capillary column (figures 1 and 2). The pyroform of the TMS-derivative was measured. The peak of the TMS-isopyroform was only about 15% of the TMS-pyroform; however, the ratio of the pyro- to the isopyro-form depends on the nature of the column.

The following masses were monitored: cholecalciferol, (M<sup>+</sup>); m/e 456 and 458 or 456 and 462, 25-hydroxycholecalciferol, (M<sup>+</sup>-90); m/e 454 and 457.




Fig. 1. GC-SIM chromatogram of trimethylsilyl ethers of cholecalciferol (a) and 25-hydroxycholecalciferol (b). GC: Capillary column SE-30 (0.29 mm i.d., 25 m), helium 1.8 ml/min. a Temperature program 220  $^{\circ}$ C-260  $^{\circ}$ C, 2  $^{\circ}$ /min, b isothermal hold at 250  $^{\circ}$ C. MS: Micromass 16F MS-apparatus, electron impact mode, 24 eV, 95  $\mu$ A trap current, ACC Voltage 4 kV, SEV Voltage 3 kV, cycle time 0.3 sec.





Fig. 2. GC-SIM chromatogram of silylated serum samples after column-, thin layer- and high-pressure liquid chromatography: *a* (cholecalciferol fraction) HPLC performed on 4% silver nitrate-silica gel column, *b* (25-hydroxycholecalciferol fraction) HPLC performed on silica gel. Details in figure 1.



GC-SIM assay of cholecalciferol and 25-hydroxycholecalciferol in serum was possible only after careful purification of serum extracts; therefore, special attention was paid to this problem. Crude serum extracts after filtration on LH-20 Sephadex<sup>8</sup> were useless because of high biological background and extremely large excess of cholesterol. Application of column- and thin layer chromatography on

alumina was also not sufficient in the assaying of 25-hydroxycholecalciferol (figure 3) because of at least 1 peak present next to the TMS-pyroform of 25-hydroxycholecalciferol.

The method described allowed the assay of both vitamins in ng levels, even when only 2 ml of serum were used. Linearity for this assay was observed between 5 and 300 ng




Fig. 3. GC-SIM chromatogram of silylated serum sample; fraction: 25-hydroxycholecalciferol. The sample was purified by column- and thin layer chromatography on alumina. Details in figure 1.

after the addition of cholecalciferol and 25-hydroxycholecalciferol to serum samples. Similar assay for 1,25-dihydroxycholecalciferol in serum is under investigation.

- 1 H.F. DeLuca and John W. Blunt, in: *Methods in Enzymology*, vol. 18C, p.709. Ed. S.P. Colowick, N.O. Kaplan, D.B. McCormick and L.D. Wright. Academic Press, New York/London 1971.
- 2 B. Garcia-Pascual, A. Peytremann, B. Courvoisier and D.E.M. Lawson, *Clin. chim. Acta* 68, 99 (1976).
- 3 M. Gemeiner, *Microchim. Acta* 1976 II, 161.
- 4 R. Bouillon, P. Van Kerkhove and P. De Moor, *Clin. Chem.* 22, 364 (1976).
- 5 P.P. Nair and Stella deLeon, *Archs Biochem. Biophys.* 128, 663 (1968).
- 6 A.P. De Leenheer and A.A.M. Cruyl, *J. chromatogr. Sci.* 14, 434 (1976).
- 7 A.A.M. Cruyl and A.P. De Leenheer, in: *Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism*, p.455. Ed. A.W. Norman, K. Schaefer, J.W. Coburn, H.F. DeLuca, D. Fraser, H.G. Grigoleit, D.V. Herrath. Walter de Gruyter, Berlin/New York 1977.
- 8 I. Björkhem and I. Holmberg, *Clin. chim. Acta* 68, 215 (1976).
- 9 J. McK. Halket and B.P. Lisboa, *Acta endocr.* 87, suppl. 215, 120 (1978).
- 10 P.W. Lambert, B.J. Syverson, C.D. Arnaud and T.C. Spelsberg, *J. Steroid Biochem.* 8, 929 (1977).
- 11 A.A.M. Cruyl, Thesis, University of Ghent, Belgium, 1976.
- 12 S. Bernstein, L. J. Binovi, L. Dorfman, K.J. Sax and Y. Subbarow, *J. org. Chem.* 14, 433 (1949).
- 13 S.J. Halkes and N.P. Van Vliet, *Rec. Trav. Chim.* 88, 1080 (1969).
- 14 T. Suda, H. F. DeLuca and R.B. Hallick, *Analyt. Biochem.* 43, 139 (1971).
- 15 P.A. Bell and W.P. Scott, *J. label. Compounds* 9, 339 (1973).
- 16 F.F. Knapp, Jr, and G.J. Schroepfer, Jr, *Chem. Phys. Lipids* 17, 466 (1976).
- 17 A.I. Ryer, W.H. Gebert and N.M. Murrill, *J. Am. chem. Soc.* 72, 4247 (1950).
- 18 W.G. Dauben and J.F. Eastham, *J. Am. chem. Soc.* 73, 4463 (1951).
- 19 The authors thank Dr. A. Fürst (F.Hoffmann-La Roche, Basel) for a sample of 3 $\beta$ -acetoxy-27-norcholest-5-en-25-one.

### The reported occurrence of L-canavanine in soya bean, *Glycine max*<sup>1</sup>

G.A. Rosenthal<sup>2</sup>

T.H. Morgan School of Biological Sciences, Lexington (Kentucky 40506, USA), 14 February 1978

**Summary.** The reported occurrence of L-canavanine in soya bean, *Glycine max* could not be verified by enzyme treatment of the extracted non-protein amino acids of the seed.

Recently, Fischer et al.<sup>3</sup> reported the putative occurrence of L-canavanine in the seed of the soya bean, *Glycine max*. This secondary plant metabolite is a principal nitrogen-storing non-protein amino acid of certain legumes<sup>4</sup>. Fischer et al.<sup>3</sup> made the interesting observation that when ground meat was adulterated with soya bean meal, automated amino acid analysis of the meat sample extract produced a ninhydrin-positive peak believed to be canavanine. This finding, if confirmed, would be important since canavanine is a highly toxic non-protein amino acid and soya bean serves as an increasingly important source of human dietary protein. Moreover, canavanine possesses potent insecticidal properties<sup>4</sup>, and, if present, could be utilized in experimental studies of toxic natural product-herbivore interaction. Several extensive plant surveys have established that canavanine's distribution is limited to the Papilionoideae (Faboideae), a major subfamily of the Leguminosae<sup>5-7</sup>,

where it has provided insight into the phylogenetic relationship of certain legumes<sup>8,9</sup>. The efforts of Tschiersch<sup>7</sup>, Bell et al.<sup>9</sup>, and Lackey<sup>10</sup> all failed to produce positive evidence for seed canavanine in *G. max*. Several ppm of canavanine have been reported in the garden onion, *Allium cepa*<sup>11</sup> and in the fungus of commerce, *Agaricus campestris*<sup>12</sup>. However, these reports have either been challenged<sup>13</sup> or have not been corroborated by independent methods for establishing and verifying minute levels of canavanine. In each instance, canavanine's purported occurrence was predicated solely upon isolation of a ninhydrin-positive substance having the column retention time of canavanine.

**Materials and methods.** The soya bean sample consisted of an approximately equal mixture of the following varieties: Woodworth, Forrest, Bonus, Dare, York, Williams, Corsoy, Essex Hood 75, and Mack. The soya bean meal (350 g), prepared as described previously<sup>14</sup>, was extracted,